Search

Displaying results 3621 - 3630 of 7186 in total
  1. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.

  2. Drug

    Difluprednate

    go.drugbank.com/drugs/DB06781
    ApprovedInvestigational

    Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or diflu...

  3. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

  4. Drug

    Lonidamine

    go.drugbank.com/drugs/DB06266
    Investigational

    In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs. … Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK).

  5. Drug

    5-methyltetrahydrofolic acid

    go.drugbank.com/drugs/DB04789
    InvestigationalNutraceutical

    It is generated by methylenetetrahydrofolate reductase from 5,10-methylenetetrahydrofolate and used to recycle homocysteine back to methionine by 5-methyltetrahydrofolate-homocysteine methyltransferases

    Synonyms: N-Methyltetrahydrofolate, N5-Methyltetrahydrofolate
  6. Drug

    Plecanatide

    go.drugbank.com/drugs/DB13170
    ApprovedInvestigational

    It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age … Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

  7. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO … [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371]

    Synonyms: N-(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-
  8. Drug

    Antilymphocyte immunoglobulin (horse)

    go.drugbank.com/drugs/DB09312
    ApprovedInvestigational

    The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. … It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen.

    Categories: Increased T Lymphocyte Destruction
  9. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. … When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins and dimerizes them, triggering downstream signaling cascade.

  10. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    [L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945] … It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.